Clinical Trial Update: Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab plus trametinib in metastatic MSS colorectal cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Trametinib (trametinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Digestive Organs, Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-06-15